Immunology & Inflammation


Evotec has developed substantial expertise in the immunology and inflammation fields and has built through collaborations and partnerships a state-of-the-art integrated drug discovery platform covering all aspects from target identification to investigational new drug (“IND”).

Our experienced immunology & inflammation team with over 30 scientists has an established and proven track record and has contributed to the discovery and development of multiple pre-clinical and clinical candidates in the area of inflammation, autoimmune disorders, pain and endometriosis.

Evotec’s core expertise in small molecule drug discovery in immunology and inflammation is complemented by a growing state-of-the-art know-how in the development of therapeutic antibodies.

Key capabilities of Evotec’s immunology & inflammation discovery platform

Phenotypic screening

  • Access complex cellular environments and use of primary cells and tissues
  • Assay platform routinely used to support both HTS and H2L/LO programmes for functional read-outs of T-cells, monocytes, macrophages, dendritic cells or other target cell types
  • Integrated into Evotec’s MS-based proteomic platform to aid target identification

In vitro pharmacology

  • Portfolio of relevant in vitro models for multiple target classes including ion channels, kinases, transporters, cytokine PPI, GPCRs, enzymes and pattern recognition receptors
  • Development and validation of novel customised assays for screening, validation and drug development
  • Specialised in CRISPR knock-out of targets in primary human lymphocytes for target identification or validation  
  • Comprehensive offering in flow cytometry/FACS ranging from high-throughput to multi-colour phenotypic characterisation
  • Human whole blood assay development for supporting human dose predictions

Rat (Sprague-Dawley)

Show fullscreen
Lung: Penumonia, fibrinonecrotising, severe, diffuse, subacute

Lung: Penumonia, fibrinonecrotising, severe, diffuse, subacute

In vivo pharmacology

  • Pharmacodynamic assays (PK/PD) including: IL-1b/desArg9 Bradykinin paw oedema, a,b-me-ATP flinching, (R)-a-methylhistamine induced dipsogenia, anti-CD3 T-cell activation/expansion, LPS cytokine release, plus a range of bespoke project-specific animal models
  • Portfolio of validated, disease relevant in vivo models in inflammation, neuro-inflammation, inflammatory bowel disease, inflammatory pain, rheumatoid arthritis, osteoarthritis, psoriasis and anaemia
  • Animal models supported by ex vivo and translational read-outs to drive key project decisions in a timely manner, including flow cytometry/FACS
  • Evotec’s translational biomarker expertise is applied to demonstrate target modulation in pre-clinical efficacy studies and to support translational biomarker read-outs that are applicable to clinical samples

Additional capabilities such as Evotec’s high-throughput screening, structure-based drug design, medicinal chemistry, bioinformatics research, DMPK, proteomics and biomarker discovery and reagent production platforms can also be accessed to support and accelerate immunology and inflammation programmes.


  • Large tool kit of functional and translational assays using primary human lymphocytes or whole blood assays
  • Expertise in many different target classes including enzymes, kinases, GPCRS, ion channels and PPI
  • Highly validated disease models in inflammation, neuro-inflammation, inflammatory pain, inflammatory bowel disease, psoriasis and anaemia
  • Animal models supported by ex vivo and translational read-outs to drive key project decisions in a timely manner

You might also be interested in

Drug discovery services In vitro biology for inflammation and immunology In vivo pharmacology for inflammation and immunology EVT Innovate

Contact us


Business Development

T +44.(0)1235.86 15 61 F +44.(0)1235.86 31 39 Get in touch with our experts vCard